COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
NanoViricides, Inc. showcases strong safety and effectiveness of lead drug NV-387 against coronaviruses, potentially filling the gap in COVID treatments. Seeking collaborations for regulatory approvals -
-
-
COMMUNIQUÉ DE PRESSE
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides, Inc. discusses development program for antiviral drug NV-387 effective against various respiratory infections, advancing towards human clinical trials -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides, Inc. elaborates on its lead broad-spectrum antiviral drug candidate NV-387, poised to revolutionize viral disease treatment. Plans include Phase II studies for RSV and market expansion
